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Subjective assessmentImpairments in executive functions (EF) in Parkinson's disease (PD) will have a negative inﬂuence on daily
life. For the assessment objective and subjective measurement approaches are used. It is however unknown
whether these approaches contribute in a different way to the assessment of EF in PD. Thirty-nine PD patients
and 24 healthy participants completed the Dysexecutive questionnaire (DEX; subjective measure) and the
Frontal Assessment Battery (FAB; objective measure). PD patients showed impaired EF (FAB) and reported
more problems with EF in daily life (DEX) than healthy participants. The performance on the FAB could
however not be explained by the problems with EF that were reported by PD patients (DEX) and vice versa. In
conclusion, not all PD patients who show impairments in EF report them and not all PD patients who report
problems with EF in daily life show impairments according to objective measurement. Both measures thus
contribute in a different way to the assessment of EF in PD patients. However, it has to be considered that the
FAB is not a critical test to assess cognition in PD, since these patients also suffer from posterior abnormalities
including memory and visuo-spatial deﬁcits which are strong predictors for PD dementia.nd Developmental Neuropsy-
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Parkinson's disease (PD) is a progressive, neurodegenerative
disorder that in the cognitive domain is characterized by impairments
in executive functions (EF), memory, visuo-spatial skills and attention
[1–3]. EF is an umbrella term for several higher order cognitive
processes that are crucial for the guidance, direction andmanagement
of cognition, emotion and behavior [4]. It includes inhibition of
automated responses, retrieval from declarative memory, planning,
monitoring, cognitive ﬂexibility and the maintenance and manipula-
tion of information in working memory [5]. In patients with PD,
impairments in these higher order cognitive processes have repeat-
edly been reported [2,6]. Cognitive impairments can have a signiﬁcant
negative inﬂuence on daily life functioning and can cause a decreased
quality of life [7]. It is therefore crucial to assess them in daily clinical
neurological practice and to consider them in patient management
and treatment. The gold standard for the assessment of executiveimpairments in PD is comprehensive neuropsychological assessment
using standardized test procedures. Because of the lack of time and
trained staff, other approaches to the assessment of EF have been
developed and introduced into clinical practice. One approach is the
use of brief screening and bedside measures such as the Frontal
Assessment Battery (FAB). The FAB is an objective bedside measure
that allows the assessment of different EF [8]. In this respect, the term
“objective” refers to the fact that performance is measured by using a
standardized assessment tool. The FAB has a good validity and
reliability and a proven sensitivity in PD [9]. Another approach is more
subjective and assesses EF by asking patients to evaluate their
problems they encounter in daily life. Since patients' reports of
troublesome symptoms may differ from the clinicians' ﬁndings, and
since these discrepancies may have an impact on the management of
PD, this subjective assessment is of particular importance. Patients'
experiences with executive problems in everyday functioning can
easily be assessed by using the Dysexecutive questionnaire (DEX). The
DEX is a standardized scale which covers a wide range of impairments
which accompany the dysexecutive syndrome and has shown to be a
sensitive instrument in several neurological populations including
Alzheimer's disease and multiple sclerosis [10–12]. The FAB and the
DEX thus appear to be reasonable approaches to the assessment of EF,
in particular because they have a very different approach (i.e.
objective standardized measurement versus subjective experience).
This is the ﬁrst study in which an objective and subjective assessment
Table 2
Scores of PD patients (n=39) and healthy participants (n=24) on the DEX and FAB.
PD patients
M (SD)
Healthy participants
M (SD)
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investigate whether an objective measurement of EF reﬂects the
problems patients encounter in daily life and vice versa.
2. Methods
2.1. Participants
Thirty-nine PD patients participated in this study. All patientswere
recruited from the Movement Disorders outpatient clinic of the
Department of Neurology of the University Medical Center Groningen
(UMCG), The Netherlands, and were diagnosed with idiopathic PD
according to the criteria of the UK Parkinson's Disease Society Brain
Bank. The motor severity of symptoms was assessed with the Hoehn
and Yahr scale (H&Y) and the Uniﬁed Parkinson's Disease Rating Scale
(UPDRS). The correlation between the two scales in our patients was
signiﬁcant (r=0.70; p≤0.001). All patients were assessed in their
regular on-state of medication. A Levodopa Equivalent Daily Dose
(LEDD) score was calculated for all patients [13]. The patient group
consisted of 22 men (56%) and 17 women (44%). In addition, 24
healthy participants were included in this study. This group consisted
of 10 men (42%) and 14 women (58%). Level of education was rated
for all participants with a Dutch education scale, ranging from 1
(elementary school not ﬁnished) to 7 (university degree). Groups did
not differ in age (t=0.20; p=0.84), gender (Chi-Square=1.29;
p=0.26) and education level (Z=−1.36; p=0.18). Descriptive and
disease characteristics of PD patients and healthy participants are
reported in Table 1. Patients with dementia (Mini Mental State
Examinationb24) and neurological disorders other than PD were
excluded. This study was approved by the medical ethical committee
of the UMCG and participants signed an informed consent prior to
study inclusion.
2.2. Stimulus material
The Dysexecutive questionnaire (DEX) is a sensitive and ecolog-
ically valid instrument [11] which consists of 20 questions that cover
the most commonly reported symptoms of the dysexecutive
syndrome. Participants were asked to rate on a scale that ranges
from 0 (never) to 4 (very often) how often they observed the
symptoms described in the DEX (DEX self). To determine whether
patients had a good insight into their daily life functioning a relative
(i.e. a partner or a child) was asked to rate how often they observed
the symptoms of the dysexecutive syndrome in their relative (DEX
other). A total score was calculated each for the DEX self and the DEX
other by adding the scores on the 20 questions. Furthermore, the
scores on the different questions of the DEX self were clustered for
each participant into three subscales as devised by Simblett andTable 1
Descriptive and disease characteristics of PD patients (n=39) and healthy participants
(n=24).
PD patients
M (SD)
Healthy participants
M (SD)
Age (years) 63.5 (8.5) 63.0 (11.7)
Educationa 5.2 (0.9) 4.8 (0.8)
MMSE total 27.5 (1.4) 27.5 (1.1)
Disease duration (years) 4.6 (3.7)
H&Y 2.2 (0.6)
UPDRS motor 24.2 (8.4)
LEDD 562.7 (446.6)
a Dutch education scale ranging from 1 (elementary school not ﬁnished) to 7
(university degree); H&Y = Hoehn and Yahr scale; UPDRS = Uniﬁed Parkinson's
Disease Rating Scale; LEDD = Levodopa Equivalent Daily Dose.Bateman [14]. These authors performed a Rasch analysis on the data of
a clinical sample of over 350 patients and deﬁned the subscales
behavioral–emotional self-regulation, metacognition and executive
cognition.
The Frontal Assessment Battery (FAB) is a short bedside instru-
ment that contains six subtests which assess different EF, including
cognitive ﬂexibility, motor programming, conceptualization, inhibi-
tion, sensitivity to interference and environmental autonomy. Each
subtest is scored between 0 and 3. A total score is calculated by adding
the scores for the subtests [8].
2.3. Statistical analyses
Tests of normality of data indicated that not all variables were
normally distributed. Since non-parametric tests are based on the
ranks of raw data, valuable information is lost and the likelihood of
false negatives is increased. Therefore, parametric tests were used
when making group comparisons and results were veriﬁed with non-
parametric tests. The results of the non-parametric tests supported
the results of the parametric tests, therefore only the results of the
parametric tests are described. T-tests for independent samples were
used to compare the performance of PD patients and healthy
participants on the DEX self total score, the subscales of the DEX
self, the DEX other total score, the FAB total score and the subtests of
the FAB. Within the group of PD patients, the scores on the DEX self
total score were compared with scores on the DEX other total score
using a t-test for related samples. Effect sizes (d) were calculated for
all comparisons. In addition, a Pearson correlation was calculated
between the DEX self total score and DEX other total score also within
the group of PD patients. Finally, two linear regression analyses
(method: enter) were performed. The ﬁrst regression analysis
determined to what extent the total score on the DEX self could be
explained by the scores on the subtests of the FAB. The second
regression analysis determined to what extent the FAB total score
could be explained by the scores on the subscales of the DEX self.
3. Results
PD patients reported signiﬁcantly more problems with EF in daily
life (DEX self total score) than healthy participants. This was reﬂected
by a signiﬁcantly higher score of PD patients on the subscale
behavioral–emotional self-regulation and a clear trend towards aDEX self
Total score 20.1 (12.1) 15.4 (5.1) 2.2 0.03 0.47
Behavioral–emotional
self-regulation
7.0 (5.1) 4.8 (2.6) 2.2 0.03 0.51
Metacognition 5.4 (3.6) 4.3 (2.1) 1.5 0.14 0.35
Executive cognition 4.5 (3.0) 3.4 (1.7) 1.9 0.06 0.50
DEX other
Total score 17.9 (12.3) 12.5 (7.3) 2.2 0.03 0.51
FAB
Total score 15.1 (2.5) 17.5 (0.6) −5.6 b0.001 1.19
Conceptualization 2.3 (1.1) 3.0 (0.0) −4.1 b0.001 0.81
Cognitive ﬂexibility 2.4 (0.8) 3.0 (0.2) −3.8 b0.001 1.46
Motor programming 2.5 (0.9) 3.0 (0.2) −3.1 b0.001 0.69
Sensitivity to
interference
2.9 (0.3) 3.0 (0.2) −0.6 0.59 0.38
Inhibition 2.0 (1.3) 2.7 (0.5) −2.8 0.01 0.65
Environmental
autonomy
3.0 (0.0) 3.0 (0.0) 0.0 1.00 0.00
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cognition (Table 2). Furthermore, PD patients did not differ from their
relatives in the number of problems with EF in daily life (t=1.3;
p=0.20; d=0.19) and the DEX self total score was signiﬁcantly
related to the DEX other total score (r=0.58; pb0.001). In the
objective measurement, PD patients showed a signiﬁcantly decreased
performance on the FAB (total score) which was reﬂected by
signiﬁcantly lower scores on conceptualization, cognitive ﬂexibility,
motor programming and inhibition (Table 2). The regression analyses
showed that the total score on the DEX self could not be explained by
the scores on the subtests of the FAB (F=0.96; p=0.45; R2=0.13).
Furthermore, the total score on the FAB could also not be explained by
the subscales of the DEX self (F=1.23; p=0.31; R2=0.06).
4. Discussion
PD patients showed impairments in EF according to the objective
measurement with the FAB, in particular in conceptualization,
cognitive ﬂexibility, motor programming and inhibition. These results
are consistent withmany previous studies focusing on cognition in PD
[1,2,6]. Furthermore, they are in line with the ﬁnding that PD patients
report more problems in daily life than healthy participants in the
domain of executive cognition, which includes high-level abilities that
are responsible for controlling and directing lower level automatic
functions through planning, monitoring, switching and inhibiting
[14]. PD patients also reported signiﬁcantly more problems than
healthy participants within the domain of behavioral–emotional self-
regulation. This domain involves emotional and reward processing
necessary for appropriate adaptive responding in the absence of
cognitive analysis, habit or environmental cues [14]. Problems with
emotional and reward processing have also been described in PD [15–
18]. Since PD patients reported the same number of problems as their
relatives it can be assumed that they had a good insight into their daily
life functioning. The results found with the objective measurement
and with the subjective assessment are thus in line with what is
known about PD. Interestingly, the performance on the objective
measurement of EF could not be explained by the problems with EF
that were reported by PD patients (only 6% of variance was
explained). Also, the problems with EF reported by PD patients
could not be explained by the objective measurement of EF (only 13%
of variance was explained). This indicates that not all PD patients who
show impairments in EF report them and that not all PD patients who
report problems with EF in daily life show impairments according to
objective measurement. An explanation is that objective measures of
EF do not always reﬂect the executive impairments patients actually
encountered in daily life. This is probably due to the fact that objective
tests are usually structured (i.e. rules and goals are set and the start
and end of behavior are prompted) and are often aimed at measuring
a single aspect of cognition [19,20] whereas situations in daily life are
usually unstructured and require sustained goal-directed collabora-
tion between various cognitive functions. Limitations in ecological
validity of objective neuropsychological measurements may thus
account for the ﬁnding that the objective measurement could not be
explained by the problems that were reported by PD patients and vice
versa. Another explanation for the divergence between the objective
and subjective assessment of executive dysfunctions in PD patients is
that the DEX was not speciﬁcally designed for patients with PD. The
DEX may therefore not fully capture the speciﬁc problems with EF in
daily life experienced by PD patients. A limitation of this study was
that only the subjective and objective assessment of EF was
investigated in PD patients. Future studies should also focus on the
subjective and objective assessment of other cognitive dysfunctions in
PD, such as impairments of memory or attention. Another limitation
was that the FAB is not the most sensitive instrument to assess
cognitive dysfunctions in PD patients. A comprehensive assessment of
EF including various measures, such as set shifting, working memoryand verbal ﬂuency, would be most desirable, but not always possible
in daily clinical practice. However, other screening instruments could
be taken into consideration in future research, in particular since
somemeasures have speciﬁcally been designed for PD, i.e. the SCOPA-
COG [21] or the PD-CRS [22]. In this respect, it is important to point
out that PD patients do not only suffer from executive dysfunctions
but also from more posterior abnormalities (i.e. memory and visuo-
spatial deﬁcits), which are also strong predictors for PD dementia [6].
Therefore, the FAB is not a critical test to assess the cognitive state of
PD patients although being a valid test for discrimination of executive
dysfunction in patients with PD, Multiple System Atrophy and
Progressive Supranuclear Palsy in particular [23]. A ﬁnal limitation
is that the present sample of PD patients was rather small and highly
selected from a specialized outpatient clinic. This might have caused
that the full range of disease severity was not expressed by the PD
population of this study. Future research on subjective and objective
assessment of cognitive dysfunctions should include a larger sample
including the full range of disease severity. In conclusion, the results of
the present study indicate that the objective measurement with the
FAB and the subjective measurement with the DEX both contribute to
the assessment of EF in PD patients. Furthermore, one type of
assessment obviously should not be exchanged for the other, since
different information is gathered by these instruments.References
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